Drug Manufacturing Licence India: Area, Schedule M & Real Costs

A drug manufacturing licence is not paperwork you file after the factory is ready. It is granted against a specific premises, a specific product list and named technical staff, after a physical inspection. The licence decides the factory.

Which means the expensive mistake in this sector is not a rejected application. It is a built facility that has to be rebuilt because the layout was never checked against Schedule M.

This guide is written for the planning stage. It gives you the minimum area prescribed for your dosage form, the gap between old and revised Schedule M, the staff qualifications that are actually checked, and an honest read on where projects lose six months.

Scope: allopathic drug manufacturing. AYUSH, cosmetics, medical devices and blood banks run on separate forms and separate authorities.

Step Zero: Which Licence Do You Need?

Your product list, not your ambition, decides the form. Get this wrong and everything downstream is wrong.

CDSCO is not the licensing authority for most of this. The state grants the manufacturing licence. CDSCO handles new drug approvals under the New Drugs and Clinical Trials Rules, 2019, imports, clinical trials and certain notified categories. Applicants routinely waste weeks approaching the wrong office.

The licence is not a product approval. A new drug needs CDSCO approval separately, and the licence covers approved categories, not an open-ended right to make anything.

The Area Table: Minimum Space by Dosage Form

This is prescribed in Schedule M and it is the first number your project plan needs, because it sets your building envelope. Figures are minimums; states may require more, and a real facility runs larger.

Three things this table tells you that a consultant's quote will not.

Beta-lactam products need a physically separate block. Not a separated room, a separate facility with its own air handling, entry and staff. If your product list mixes penicillins or cephalosporins with general products, you are building two plants.

Injectables are a different business. 250 m² minimum against 80 m² for tablets, plus environmental classification, validated sterilisation, and higher-qualified staff. The step from Form 25 to Form 28 is not an upgrade; it is a new project.

These are production sections only. Warehouse, quarantine, QC laboratory, change rooms, utilities and offices sit outside these figures. A unit planning an 80 m² tablet section needs perhaps three times that in total built area.

The Revised Schedule M Gap Checklist

This is the most urgent item in the sector and the thing most likely to catch an existing unit. Revised Schedule M aligns Indian GMP with WHO-GMP, PIC/S and ICH Q10 for the first time, and it added systems that simply did not exist in the old text.

Use this as a self-audit. If you cannot evidence the right-hand column with a document, you have a gap.

Where existing units actually fail. In practice the inspection findings are not usually about walls. They are PQS not documented, no product quality reviews on file, computerised systems unvalidated, and supplier qualification missing. Those are systems and documentation gaps, which sounds easier than construction, and is not: building a real quality system and generating a year of records takes months.

Where the deadline stands. The compliance timeline for small and medium manufacturers with turnover below ₹250 crore was extended to 31 December 2025, with eligible units required to register on the ONDLS portal and file a gap analysis covering plant, equipment, HVAC and utilities, plus an item-wise compliance plan. Reporting in late December 2025 indicated no further extension, and CDSCO directed state regulators to begin inspections under the revised norms. Roughly 2,000 of India's approximately 8,500 MSME pharma units held WHO-GMP certification at the time of the extension, which indicates the scale of the upgrade still outstanding.

Verify this before acting on it. The position moved several times through 2024 and 2025, and state-level practice varies. Confirm current enforcement with your State Drugs Controller.

Technical Staff: What Is Actually Checked

The Rules require competent technical staff, whole time, and the Licensing Authority approves them individually. This is not a name on a form.

What the file must contain for each person: self-attested qualification certificates, experience certificates, biodata on the prescribed proforma, appointment letter and acceptance, photographs, and an affidavit of whole-time employment sworn by both the employer and the staff member.

That last document exists because borrowed names are a known practice. Both sides swear to it, which makes it a personal exposure rather than a paperwork item. Treat the appointment as real, because the regulator does.

The Sequence, With Honest Timelines

The pattern worth internalising: applicants budget for phase 3 and are surprised by phases 2 and 7. Time spent on the layout before construction is the cheapest time in the whole project. Time spent rectifying after inspection is the most expensive.

Costs: The Licence Fee Is Not Your Cost

The statutory fee is trivial relative to the project, and quoting it as "the cost of a drug licence" is misleading.

What determines your budget is the product category, not the fee schedule. An oral solid dosage unit and a small volume injectables unit differ by an order of magnitude, because of area (80 m² vs 250 m²), environmental classification, and validation load. Confirm current fees with your State Drugs Control Department; these are state notified and revised periodically.

One location constraint that catches people: several states grant manufacturing licences only in notified industrial areas. Delhi's Drugs Control Department states this as departmental policy. Check before you acquire land.

Own Plant or Loan Licence? Decide This Before Anything Else

Most people searching for a manufacturing licence want a pharma brand, not a factory. Those are different projects and the loan licence exists for the first one.

The honest advice: if you have not yet proven the brand can sell, a loan licence is almost always the right first step. Build the plant when volume justifies it, not to look like a manufacturer.

One diligence item people skip: before signing with a host unit, check its Schedule M position. If your contract manufacturer is one of the units that has not upgraded, your supply stops when the regulator arrives. Ask to see their ONDLS gap analysis and compliance plan.

Frequently Asked Questions

Which form do I need for a drug manufacturing licence? Form 24 for drugs other than Schedules C, C(1) and X, with the licence granted in Form 25. Form 27 for Schedule C and C(1) drugs such as injectables, with the licence in Form 28. Form 24A for a loan licence, granted in Form 25A.

Does CDSCO or the state issue the manufacturing licence? The State Licensing Authority, that is the State Drugs Controller, for most drugs. CDSCO handles new drug approvals, imports, clinical trials and certain notified categories.

What is the minimum area for a tablet manufacturing unit? Schedule M prescribes 60 m² for the uncoated tablet section plus 20 m² ancillary, so 80 m² minimum, with a further 40 m² if you add coating. Warehouse, QC laboratory, change rooms and utilities are additional.

Can I make beta-lactam and general products in the same facility? No. Beta-lactam products require a physically separate block with independent air handling and staff entry. Schedule M prescribes separate areas for beta-lactam tablets and capsules.

What qualification does the technical staff need? At minimum one whole-time graduate in Pharmacy or Pharmaceutical Chemistry, or a graduate in Science with Chemistry, with around 18 months of practical experience in drug manufacture. Schedule C and C(1) manufacture requires higher qualifications. Whole-time employment affidavits are required from both the employer and the staff member.

What is a loan licence in pharma? A licence permitting you to manufacture your own branded products at another licensee's approved premises, using their plant and staff. Applied for in Form 24A, granted in Form 25A. It is the standard route for marketing companies without a plant.

How much does a drug manufacturing licence cost? The statutory fee is small; Delhi's published schedule shows ₹6,000 licence fee and ₹1,500 inspection fee. The real cost is the Schedule M compliant premises, HVAC, water system and QC laboratory, which varies by an order of magnitude between oral solids and injectables.

What is the deadline for revised Schedule M compliance? It was extended to 31 December 2025 for manufacturers with turnover below ₹250 crore who applied through ONDLS with a gap analysis. Reporting in late 2025 indicated no further extension and CDSCO directed states to start inspections. Confirm the current position with your State Drugs Controller.

How long does it take to get a manufacturing licence? There is no reliable statutory timeline in practice. Where the layout meets Schedule M and the documentation is complete at inspection, a few months is realistic. Deficiencies and re-inspection are what extend it, often by several months.

What is the validity of a drug manufacturing licence? Typically five years, subject to state rules and payment of renewal or retention fees within the prescribed period. Late renewal attracts additional fees and beyond a point requires a fresh application.

Do I need a WHO-GMP certificate as well? Schedule M compliance is a condition of the licence itself. WHO-GMP certification and a Certificate of Pharmaceutical Product are separate, applied for on the basis of the licence, and required for many export markets.

What happens if I manufacture without a licence? It is an offence under the Drugs and Cosmetics Act, 1940, carrying penal consequences including imprisonment, with stock liable to seizure. This is not a regularise-later situation.